UBS maintains Buy on Veracyte; price target raised to $65
UBS maintains a Buy rating on Veracyte and raises its price target to $65.00 per share from $52.00, per Benzinga via TradingView News.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.